Cargando…
508. Nirmatrelvir/ritonavir use among patients with cancer and COVID-19 is associated with improved clinical outcomes: Single-institution case-control study
BACKGROUND: Patients with cancer are at increased risk for severe and lethal COVID-19, compared to the general population. Currently, with no anti-spike monoclonal antibodies available against circulating variants of SARS-CoV-2, the logistic limitations of outpatient remdesivir infusions, and lack o...
Autores principales: | Arvanitis, Panos, Vieira, Kendra, Warner, Jeremy L, Farmakiotis, Dimitrios |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678017/ http://dx.doi.org/10.1093/ofid/ofad500.577 |
Ejemplares similares
-
631. Using a commercially available assay that measures cytomegalovirus (CMV)-specific CD4+ and CD8+ T-cell immunity to predict protection against CMV: Results from a prospective, blinded clinical trial
por: Almaghlouth, Nouf K, et al.
Publicado: (2023) -
523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023) -
483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023) -
Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022) -
Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)